Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Bets On Blockbuster Hypertension Market With Ardian Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's $800-million-plus bet on still-early-stage catheter technology for treating hypertension is a risk worth taking, company watchers suggest, considering many of the device giant's core offerings are in mature markets with paltry growth prospects.

You may also be interested in...



Cardio Catch-Up: Medtronic Still Has Work To Do On RDN After FDA Advisory Panel

FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.

Symplicity Makes Life Difficult For Renal Denervation Programs

A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint

Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition

Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel